Nanobiotix Raises Over $53 Million in Capital Increases

PARIS and CAMBRIDGE, Mass. – Nanobiotix, a late-stage clinical biotechnology company, has announced the completion of two capital increases that generated approximately $53.6 million in gross proceeds. The company also confirmed the availability of a listing prospectus, approved by the French Financial Markets Authority (AMF) on November 3.

The first capital increase, subscribed by qualified investors, raised approximately $30 million in gross proceeds. This was supplemented by the partial exercise of an over-allotment option, adding about $3.6 million. The second capital increase involved Johnson & Johnson Innovation – JJDC, Inc. (JJDC), which subscribed for approximately $20.2 million. While JJDC initially agreed to subscribe for $25 million, a portion of this investment, around $4.8 million, is subject to approval from the French Ministry of Economy and Finance. This potential future investment could bring the total proceeds raised prior to the exercise of overallotment options close to $55 million.

Nanobiotix focuses on developing physics-based therapeutic approaches to expand treatment possibilities for cancer patients. The company is listed on Euronext Paris and the Nasdaq Global Select Market in New York. Its lead product candidate, NBTXR3, has received CE marking in Europe for the treatment of soft tissue sarcoma under the brand name Hensify®.

According to Nanobiotix, the AMF-approved prospectus provides detailed information regarding the terms of these share capital increases. The company has made these documents, including its 2022 universal registration document and subsequent amendments, available on its corporate website and the AMF's website.

The capital raised is expected to support the ongoing development and clinical advancement of Nanobiotix's pipeline, particularly its lead NBTXR3 asset.